Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index; 15 of the 26 sources its claims cite were checked for support.

Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.

Open access

Abstract

This phase 2 randomized placebo-controlled trial included parallel cohorts of patients with IPF and PPF treated with admilparant 30 mg, 60 mg, or placebo for 26 weeks; the 60 mg dose showed numerically better preservation of ppFVC, especially in PPF.

Overview

CoChat Summary

TL;DR

This phase 2 randomized, double-blind, placebo-controlled trial found that 60 mg twice daily of admilparant, an oral LPA1 antagonist, slowed 26-week lung function decline in both IPF and PPF cohorts. The drug was generally safe and well tolerated, with diarrhea and transient blood pressure reductions being the main safety signals.

Key findings

  • In the IPF cohort, the 26-week rate of change in ppFVC was -2.7% with placebo, -2.8% with 30 mg, and -1.2% with 60 mg; the 60 mg vs placebo treatment difference was 1.4% (95% CI, -0.1 to 3.0) under the treatment-policy estimand and 1.8% (95% CI, 0.2 to 3.4) under the while-on-treatment estimand.
  • In the PPF cohort, the 26-week rate of change in ppFVC was -4.3% with placebo, -2.9% with 30 mg, and -1.1% with 60 mg; the 60 mg vs placebo treatment difference was 3.2% (95% CI, 0.7 to 5.7) under the treatment-policy estimand and 3.0% (95% CI, 0.4 to 5.6) under the while-on-treatment estimand.
  • Bayesian analysis in the IPF cohort gave a posterior probability of >95% for a positive treatment difference for 60 mg admilparant vs placebo under both estimand strategies.
  • Safety was broadly comparable across arms: TEAEs occurred in 80%/76%/74% of IPF patients and 78%/83%/67% of PPF patients in placebo/30 mg/60 mg arms, respectively; serious TEAEs and discontinuations were generally lower with admilparant than placebo, especially in PPF (discontinuations 17% placebo vs 3% and 0% with 30 mg and 60 mg).

Methods

  • Phase 2, randomized, double-blind, placebo-controlled trial with parallel IPF and PPF cohorts at 79 sites in 17 countries; 1:1:1 randomization to 30 mg admilparant, 60 mg admilparant, or placebo twice daily for 26 weeks.
  • Sample: 403 randomized (278 IPF, 125 PPF); 399 treated (276 IPF, 123 PPF). Background antifibrotics were allowed in both cohorts, and ILD-targeted immunosuppressants were allowed in PPF.
  • Primary endpoint was change in percentage of predicted FVC (ppFVC) from baseline to week 26; analyses used linear mixed-effects models, a two-estimand framework (treatment-policy and while-on-treatment), and a Bayesian supportive analysis for the IPF cohort.

Limitations

  • The paper states that the study was not powered to claim statistical significance, and results are estimation-based.
  • The 26-week duration was not sufficient to determine whether FVC effects translate into long-term outcomes such as quality of life or hospitalizations; the authors say larger and longer trials are needed.
  • The small number of patients not on background antifibrotics limited firm subgroup conclusions; this is stated in the paper.
  • Evident from the text: PPF was heterogeneous and the cohort excluded connective tissue disease ILD other than rheumatoid arthritis-associated ILD, so generalizability to other immune-mediated ILDs is limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1164/rccm.202405-0977oc

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

11 Valid · 2 Not valid · 4 Not checked · 73 Own results and interpretations

38 more claims

Create a free account to see all 90 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 32
  • Probably not a substantial claim. 21
  • Borderline: one of the tests for a substantial claim is unclear. 1
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Citations

Cites

Show all 16 references

Cited by

See all 70

Metadata

Authors
Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., Elpers, B., Kim, S., Watanabe, H., Fischer, A., & Maher, T. M.
Affiliations
  • The University of Sydney (AU)
  • Department of Medicine V, LMU University Hospital, LMU Munich, Member of the German Center for Lung Research, Munich, Germany
  • Hospices Civils de Lyon (FR)
  • Loyola University Chicago (US)
  • University Medical Center of the Johannes Gutenberg University Mainz (DE)
  • Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, New York
  • Kanagawa Cardiovascular and Respiratory Center (JP)
  • Hamamatsu University (JP)
  • Erasmus MC (NL)
  • Bristol-Myers Squibb (United States) (US)
  • University of Southern California (US)
Corresponding author
Maher, Toby M.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2025-02-01
Volume
211
Issue
2
Pages
230-238
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W4403320879
Cited by
70
References
16
Citations by year
2026: 40 · 2025: 28
FWCI
20.20
Type
journal article
Language
en
Open access
Locations
  • American Journal of Respiratory and Critical Care Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
Funders
Bristol Myers Squibb
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, lung function, drug safety, diarrhea, hypotension, adverse events, dose comparison, immunosuppressants
MeSH terms
Antifibrotic Agents, Aged, Double-Blind Method, Female, Humans, Male, Middle Aged, Pulmonary Fibrosis, Vital Capacity, Treatment Outcome, Receptors, Lysophosphatidic Acid, Idiopathic Pulmonary Fibrosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. https://app.cochat.ai/papers/10.1164/rccm.202405-0977oc
The paper
Corte, T. J., Behr, J., Cottin, V., Glassberg, M. K., Kreuter, M., Martinez, F. J., Ogura, T., Suda, T., Wijsenbeek, M., Berkowitz, E., Elpers, B., Kim, S., Watanabe, H., Fischer, A., & Maher, T. M. (2025). Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.202405-0977oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.